Aarti Drugs Limited Receives Administrative Warning from SEBI
On March 6, 2025, Aarti Drugs Limited announced through its exchange filing that it has been issued an administrative warning letter from the Securities and Exchange Board of India (SEBI). This warning is connected to an investigation into the trading activities of certain entities associated with the company’s shares.
Findings from SEBI’s Investigation
The warning highlighted deficiencies in the company’s compliance measures, noting that the firm had not sufficiently identified all immediate relatives of designated persons and had failed to apply its Code of Conduct on Prohibition of Insider Trading (PIT) to these individuals.
Company’s Response
In light of the findings, Aarti Drugs Limited has assured the market regulator of its commitment to adhere to regulatory requirements and to implement necessary precautions to prevent similar occurrences in the future. The company stated, “There is no penalty or restriction or sanction imposed,” as confirmed in their regulatory filing.
Conclusion
The actions taken by SEBI reflect the authority’s commitment to maintaining market integrity. Aarti Drugs Limited’s proactive response to the warnings demonstrates its intention to enhance compliance efforts moving forward.
